Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- SMSI -20.8%, (sees Q3 revs of $6.5 mln, prior guidance was for $7.9-8.4 mln, vs $8.20 mln two analyst estimate)
- HIVE -20.6%, (guides Q3 revenues below expectations; Sees EPS at low end of prior guidance)
- NHTC -14.3%, (Natural Health Trends sees Q3 revenue down 12% to $70.7 mln )
- ONCS -4%, INFY -3.9%, SERV -2.8%, DFRG -2.3%
- HPQ -1.7%, (guides FY17 adj. EPS in-line; raises dividend 7%; adds $3 bln to buyback; announces restructuring with 3-4K expected layoffs)
- SKY -0.7%
M&A news:
- SYT -1.3% (Bloomberg report that China may look to merge ChemChina with Sinochem Group; Syngenta agreed to be acquired by ChemChina in February for ~$43 bln)
Select metals/mining stocks trading lower: AU -1.4%, KGC -1.3%, ABX -1.3%, GDX -1.3%, NEM -1.3%
Other news:
Other news:
- BIOC -21.6% (prices a 9.1 mln share underwritten public offering of common stock & warrants)
- OPTT -20.9% (filed a form EFFECT (Notice of Effectiveness for a Form S-1))
- LMRK -7.3% (announces a 3 mln common unit underwritten public offering representing limited partner interests)
- EGLT -5.6% (Egalet notified that FDA will not meet October 14 PDUFA goal data for ARYMO ER; No additional scientific information or data requested by FDA)
- WMIH -2.8% ( Appaloosa LP lowers passive stake to 3.7%)
- RSPP -2.5% (upsizes offering by 2 mln shares; prices 22 mln shares of its common stock at $39.75 per share)
- DPRX -1.4% (after closing near lows)
Analyst comments:
- BETR -2.9% (downgraded to Neutral from Buy at Goldman)
- SEDG -2.7% (initiated with a Sell at Axiom Capital)
- BLUE -2.1% (downgraded to Sell from Hold at Cantor Fitzgerald)
- ROLL -1.4% (downgraded to Neutral at Seaport Global Securities)